RJA
EXEL icon

Raymond James & Associates’s Exelixis EXEL Stock Holding History

Raymond James & Associates’s Portfolio EXEL Stock Details EXEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$6.22M Buy
239,661
+129,805
+118% +$3.23M ﹤0.01% 1506
2024
Q2 		$2.47M Buy
109,856
+1,328
+1% +$29.5K ﹤0.01% 2033
2024
Q1 		$2.58M Sell
108,528
-5,103
-4% -$113K ﹤0.01% 2002
2023
Q4 		$2.73M Buy
113,631
+4,185
+4% +$91K ﹤0.01% 1907
2023
Q3 		$2.39M Sell
109,446
-28,653
-21% -$599K ﹤0.01% 1908
2023
Q2 		$2.64M Sell
138,099
-13,509
-9% -$260K ﹤0.01% 1884
2023
Q1 		$2.94M Buy
151,608
+11,721
+8% +$204K ﹤0.01% 1811
2022
Q4 		$2.24M Sell
139,887
-2,508
-2% -$40.9K ﹤0.01% 1922
2022
Q3 		$2.23M Buy
142,395
+58,734
+70% +$1.13M ﹤0.01% 1902
2022
Q2 		$1.74M Sell
83,661
-14,967
-15% -$308K ﹤0.01% 2068
2022
Q1 		$2.24M Buy
98,628
+6,104
+7% +$119K ﹤0.01% 2046
2021
Q4 		$1.69M Sell
92,524
-10,336
-10% -$198K ﹤0.01% 2287
2021
Q3 		$2.17M Buy
102,860
+56,512
+122% +$1.05M ﹤0.01% 2041
2021
Q2 		$844K Sell
46,348
-801
-2% -$18.7K ﹤0.01% 2710
2021
Q1 		$1.06M Sell
47,149
-1,659
-3% -$37.5K ﹤0.01% 2464
2020
Q4 		$980K Buy
48,808
+914
+2% +$19.1K ﹤0.01% 2362
2020
Q3 		$1.17M Sell
47,894
-2,485
-5% -$58K ﹤0.01% 2087
2020
Q2 		$1.2M Buy
50,379
+6,344
+14% +$147K ﹤0.01% 2036
2020
Q1 		$758K Sell
44,035
-72,347
-62% -$1.32M ﹤0.01% 2154
2019
Q4 		$2.05M Sell
116,382
-2,752
-2% -$46.6K ﹤0.01% 1814
2019
Q3 		$2.11M Sell
119,134
-29,630
-20% -$600K ﹤0.01% 1745
2019
Q2 		$3.18M Sell
148,764
-197,851
-57% -$4.15M ﹤0.01% 1502
2019
Q1 		$8.25M Buy
346,615
+99,163
+40% +$2.26M 0.01% 915
2018
Q4 		$4.87M Sell
247,452
-2,967
-1% -$52.9K 0.01% 1122
2018
Q3 		$4.44M Buy
250,419
+173,104
+224% +$3.38M 0.01% 1290
2018
Q2 		$1.66M Buy
77,315
+28,714
+59% +$594K ﹤0.01% 1883
2018
Q1 		$1.08M Sell
48,601
-31,596
-39% -$873K ﹤0.01% 2082
2017
Q4 		$2.44M Buy
80,197
+51,431
+179% +$1.37M ﹤0.01% 1563
2017
Q3 		$697K Buy
+28,766
New +$766K ﹤0.01% 2294

Other funds holding EXEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Raymond James & Associates's EXEL Position: Q3 2024 in Review

Raymond James & Associates increased its Exelixis (EXEL) stake by 118% in Q3 2024, buying an estimated $3.23M and bringing the position to 239,661 shares worth $6.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1506.

Raymond James & Associates first reported a position in EXEL in Q3 2017 and has held it in 29 quarters since. The position peaked at $8.25M in Q1 2019. 453 funds tracked by Wall St. Rank hold EXEL as of Q3 2024.

  • Raymond James & Associates held 239,661 shares of Exelixis worth $6.22M as of Q3 2024.
  • Raymond James & Associates bought 129,805 Exelixis shares in Q3 2024, an estimated $3.23M.
  • Exelixis made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1506 holding.
  • Raymond James & Associates first reported a position in Exelixis in Q3 2017 and has held it in 29 quarters since.
  • Raymond James & Associates's Exelixis position peaked at $8.25M in Q1 2019.
  • 453 funds tracked by Wall St. Rank held Exelixis as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.